Changes in Beneficial Ownership · 4
Vogenx, Inc.
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-02
- Issuer
- Vogenx, Inc.
- Issuer CIK
- 0001903784
- Trading symbol
- VOGX
Reporting owner 1
- Name
- DELMAR STEVEN R
- Reporting owner CIK
- 0001272302
- Relationship
- Director · Officer
- Officer title
- Chief Financial Officer
- Address
- C/O VOGENX, INC, PO BOX 19469, RALEIGH, NC, 27619
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 18.23 | 2026-10-02 | A · Form 4 | 155,000 | A | 0 | [F1] | 2036-10-02 | Common Stock | 155,000 | 155,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The options vest over a three -year period in three equal annual installments of 33.33% (51,666 shares on October 2, 2027, 51,667 shares on October 2, 2028 and 51,667 shares on October 2, 2029), subject to the Reporting Person's continued service to the Issuer through each vesting date.↩ 1
Signature 1
- Signed
- /s/ Steven R Delmar
- Date
- 2026-10-06
Company context
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 9, 2026
- 4 filingOct 6, 2026
- 4 filingOct 6, 2026
- 4 filingOct 6, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 22, 2026